Cancer-testis antigen MAGE-C2/CT10 induces spontaneous CD4+ and CD8+ T-cell responses in multiple myeloma patients

Blood Cancer Journal

Volumn 4, Issue 5, 2014, Pages

  Reinhard, H ^a   Yousef, S ^a,b   Luetkens, T ^a,b   Fehse, B ^a   Berdien, B ^a   Kroger N ^a   Atanackovic, D ^a,b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER TESTIS ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; MAGE C2 ANTIGEN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; EPITOPE; MAGEC2 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR PROTEIN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; CANCER PATIENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LETTER; MEMORY T LYMPHOCYTE; MULTIPLE MYELOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; ADOPTIVE IMMUNOTHERAPY; BLOOD; IMMUNOLOGY; PROCEDURES;

ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES; EPITOPES, B-LYMPHOCYTE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MULTIPLE MYELOMA; NEOPLASM PROTEINS;

EID: 84901980428     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2014.31     Document Type: Letter

References (15)

1. Blade J, Cibeira MT, Fernandez de Larrea C, Rosinol L. Multiple myeloma. Ann Oncol 2010; 21(Suppl 7): vii313-vii319.
2. Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood 2012; 120: 947-959.
3. Quach H, Kalff A, Spencer A. Lenalidomide in multiple myeloma: current status and future potential. Am J Hematol 2012; 87: 1089-1095.
4. Gure AO, Stockert E, Arden KC, Boyer AD, Viars CS, Scanlan MJ et al. CT10: a new cancer-testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational-difference analysis. Int J Cancer 2000; 85: 726-732.
5. Lucas S, De Plaen E, Boon T. MAGE-B5, MAGE-B6, MAGE-C2, and MAGE-C3: four new members of the MAGE family with tumor-specific expression. Int J Cancer 2000; 87: 55-60.
6. Pabst C, Zustin J, Jacobsen F, Luetkens T, Kroger N, Schilling G et al. Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma. Exp Mol Pathol 2010; 89: 175-181.
7. de Carvalho F, Alves VL, Braga WM, Xavier Jr. CV, Colleoni GW. MAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy. Cancer Immunol Immunother 2013; 62: 191-195.
8. Atanackovic D, Arfsten J, Cao Y, Gnjatic S, Schnieders F, Bartels K et al. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood 2007; 109: 1103-1112.
9. Bhatia N, Xiao TZ, Rosenthal KA, Siddiqui IA, Thiyagarajan S, Smart B et al. MAGE-C2 promotes growth and tumorigenicity of melanoma cells, phosphorylation of KAP1, and DNA damage repair. J Invest Dermatol 2013; 133: 759-767.
10. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME et al. Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1. J Clin Oncol 2011; 29: 917-924.
11. Noonan K, Matsui W, Serafini P, Carbley R, Tan G, Khalili J et al. Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors. Cancer Res 2005; 65: 2026-2034.
12. Dhodapkar MV, Krasovsky J, Olson K. T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. Proc Natl Acad Sci USA 2002; 99: 13009-13013.
13. Pellat-Deceunynck C, Jego G, Harousseau JL, Vie H, Bataille R. Isolation of human lymphocyte antigens class I-restricted cytotoxic T lymphocytes against auto-logous myeloma cells. Clin Cancer Res 1999; 5: 705-709.
14. Hayashi T, Hideshima T, Akiyama M, Raje N, Richardson P, Chauhan D et al. Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood 2003; 102: 1435-1442.
15. Lokhorst HM, Wu K, Verdonck LF, Laterveer LL, van de Donk NW, van Oers MH et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004; 103: 4362-4364.